Press Release

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis

– Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami – GAITHERSBURG, Md., May 10, 2022  – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients …

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis Read More »

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma

Descartes-25 engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment Product generated from Company’s Part 1271-compliant Master Cell Bank of human umbilical cord Mesenchymal Stem Cells Fifth IND in the five years since Cartesian was founded Gaithersburg, Md., January 25, 2022 – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company …

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma Read More »

Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors

Gaithersburg, Md., Dec. 14, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the appointment of five internationally recognized Senior Advisors to support its growing clinical pipeline for autoimmune, respiratory, and inflammatory diseases.  Cartesian’s new appointments include distinguished physicians, scientists, professors, and industry experts …

Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors Read More »

Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer

Former CMO Metin Kurtoglu, M.D., Ph.D., appointed as the Company’s first Chief Operating Officer Cartesian expands cGMP manufacturing facility to support growing clinical pipeline Gaithersburg, Md., Sept. 28, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the hire of Miloš Miljković, M.D., as …

Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer Read More »

Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis

In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial improvement in Myasthenia Gravis Composite scale. Descartes-08 was well tolerated in all three patients Gaithersburg, MD, August 24, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering …

Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis Read More »

Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies

Award increases NIH funding to $6.3 million to date from three independent NIH Institutes. Gaithersburg, MD, May 4, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced a $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National …

Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies Read More »

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer

Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without requiring lymphodepleting chemotherapy Cartesian plans to enroll up to 30 patients in a single arm, open-label, multicenter study Gaithersburg, MD, Feb. 22, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today …

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Read More »

Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19

Descartes-30 engineered to express a unique combination of DNases to eliminate neutrophil extracellular traps (NETs), a key driver of inflammation and clotting in ARDS. Gaithersburg, MD, September 1, 2020 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer, autoimmune diseases and respiratory diseases, today announced that it has …

Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19 Read More »

Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis

First CAR-T to enter clinical development for an autoimmune disease  Descartes-08 engineered to have a defined, predictable half-life, enabling repeat dosing to maximize potential for potency while minimizing risk of toxicity Gaithersburg, MD, November 5, 2019 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer and autoimmune diseases, …

Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis Read More »

Scroll to Top